Cogent Biosciences (COGT) announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer ...

They used cells that normally express ERBB2, and they added the HSP90 inhibitor ... showed that HSP90 inhibitors caused depletion of EGFR, the most well known ERBB, over time (Sakagami, Morrison ...

EGFR has been the most extensively studied with ... Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer 9, 463–475 (2009) doi:10.1038/nrc2656.

Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of the HER2 receptor, and lapatinib, a dual reversible EGFR/HER2 TKI, are indicated for the treatment of HER2 ...

All posters will be available on the ‘Posters and Publications’ page of Cogent’s website. New Leadership Appointments Cogent also announced today that Ray Frost has joined Cogent as Senior Vice ...

Using microarrays to perform a genome-wide assessment of the receptor network, they found that EGFR and ErbB2 bind to proteins more promiscuously, and activate many more signaling pathways, as they ...

While approximately 80% of never-smoking lung cancer patients are prescribed targeted therapies that focus on mutations in proteins such as EGFR and ALK ... such as STK11 and ERBB2, were observed ...

The Rybrevant-Lazcluze combo significantly reduced the risk of death by 25% versus Tagrisso in patients with newly diagnosed advanced EGFR-mutated NSCLC, according to data from the phase 3 ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...